COHERUS ONCOLOGY INC (CHRS:NASDAQ)
$1.41 -0.01 (-0.7042%)
Analysed COHERUS ONCOLOGY INC (CHRS:NASDAQ) News Sources
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
04-05-2026
yahoo.com
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
05-05-2026
yahoo.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
11-05-2026
247wallst.com
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11-05-2026
yahoo.com
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
11-05-2026
yahoo.com
Coherus Oncology Q1 Earnings Call Highlights
11-05-2026
marketbeat.com
Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...
12-05-2026
yahoo.com
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary
12-05-2026
moby.co
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today
14-05-2026
yahoo.com
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
11-06-2026
yahoo.com
What is the current price of COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The current price of COHERUS ONCOLOGY INC (CHRS:NASDAQ) is $1.41.
COHERUS ONCOLOGY INC (CHRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of COHERUS ONCOLOGY INC (CHRS:NASDAQ) since the previous trading day is $-0.01.
COHERUS ONCOLOGY INC (CHRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of COHERUS ONCOLOGY INC (CHRS:NASDAQ) since the previous trading day is -0.7042%.
What is the most recent average sentiment score for COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The most recent average sentiment score for COHERUS ONCOLOGY INC (CHRS:NASDAQ) is 39 out of 100.
What is the most recent average sentiment for COHERUS ONCOLOGY INC (CHRS:NASDAQ)?
The most recent sentiment for COHERUS ONCOLOGY INC (CHRS:NASDAQ) is .
SEC-8K** Filing Available For COHERUS ONCOLOGY INC (CHRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.